Table 1 Treatment Arms in the WIRE trial. bd: twice daily, IMP: Investigational Medicinal Product, i.v.: intravenous, od: once daily. Dose reductions permissible in case of toxicity
Arm | IMP | Dosing, Stopping and Dose Adjustments |
|---|---|---|
1 | Cediranib | 20 mg oral od, until 36 h before surgery, single reduction to 15 mg od |
2 | Cediranib + Olaparib | Cediranib 20 mg oral od and Olaparib 300 mg oral bd, stopping and dose adjustments as in single-agent arms |
3 | Olaparib | 300 mg oral bd, until morning of surgery, two reductions to 250 mg bd and 200 mg bd |
4 | Durvalumab | 1500 mg i.v. (single infusion) |
5 | Olaparib + Durvalumab | Olaparib 300 mg oral bd and Durvalumab 1500 mg i.v. (single infusion). Stopping and dose adjustment for Olaparib as in single-agent arm above. |